Tessa Adzemovic, Elizabeth Nalintya, Philips Onencan, Oduc Enock, Josephine Badaru, Malak Elshafei, David R Boulware, David B Meya, Radha Rajasingham
The Visitect CD4 Advanced Disease platform is a rapid, semi-quantitative assay that estimates CD4 results above or below 200 cells/μL and can be performed on venous whole blood or by fingerprick. We conducted a prospective validation of the Visitect CD4 Advanced Disease platform via fingerprick versus venous whole blood. Overall, there was 95.5% agreement (149/156). The high level of agreement between the fingerprick and venous whole blood results may support the use of the fingerprick Visitect CD4 test as a reliable point-of-care diagnostic tool in settings where access to conventional venous whole blood testing may be limited.